Immunotherapy of acute myeloid leukemia

A. E. Frankel, M. R. Baer, D. E. Hogge, R. K. Stuart

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Most patients with acute myeloid leukemia (AML) respond initially to combination chemotherapy but later relapse. These patients often die from progressive disease or toxicities of further chemotherapy. At relapse, the patients' blasts are usually resistant to the drugs to which the patient has been exposed and frequently to other cytotoxic agents as well. Nevertheless, a number of these patients may be salvaged and achieve remissions with allogeneic stem cell transplants. In such cases, the pre-transplant conditioning regimens do not appear to account for the entire anti-leukemic efficacy. Immunological mechanisms for blast killing appear critical. There is tissue culture, animal and clinical evidence that stimulated donor T cells can recognize and kill leukemic blasts through recognition of alloantigens, differentiation antigens or leukemia-specific antigens as targets. We will review the molecular mechanisms for the generation of anti-leukemic T cells and discuss methods to improve the specificity and intensity of anti-leukemic T cell responses in the setting of allogeneic stem cell transplants, donor lymphocyte infusions, autologous anti-leukemic T cell infusions, and vaccine use in AML patients.

Original languageEnglish (US)
Pages (from-to)209-215
Number of pages7
JournalCurrent Pharmaceutical Biotechnology
Issue number3
StatePublished - Sep 11 2001

ASJC Scopus subject areas

  • Biotechnology
  • Pharmaceutical Science


Dive into the research topics of 'Immunotherapy of acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this